From WikiProjectMed
(Redirected from Valproate semisodium)
Jump to navigation Jump to search
INN: valproic acid
Trade namesDepakote, Epilim, Convulex, others
Other namesValproic acid; Sodium valproate (sodium); Valproate semisodium (semisodium); 2-Propylvaleric acid
  • 2-propylpentanoic acid
Clinical data
  • AU: D
  • US: X (Contraindicated)- only for epilepsy or bipolar if other options are not possible[1]
Routes of
By mouth, intravenous
Defined daily dose1.5 g (by mouth) or
1.5 g (parenteral) or
1.5 g (rectal)[2]
External links
License data
Legal status
BioavailabilityRapid absorption
Protein binding80–90%[3]
MetabolismLiverglucuronide conjugation 30–50%, mitochondrial β-oxidation over 40%
Elimination half-life9–16 hours[3]
ExcretionUrine (30–50%)[3]
Chemical and physical data
Molar mass144.211 g·mol−1
3D model (JSmol)
  • InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10) checkY

Valproate (VPA) and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches.[1] They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures.[1] They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.[1]

Common side effects of valproate include nausea, vomiting, sleepiness, and dry mouth.[1] Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended.[1] Other serious risks include pancreatitis and an increased suicide risk.[1] Valproate is known to cause serious abnormalities in babies if taken during pregnancy,[1][4] and as such it is not typically recommended for women of childbearing age who have migraines.[1]

Valproate's precise mechanism of action is unclear.[1][5] Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, and inhibiting histone deacetylases.[6][7] Valproic acid is a branched short-chain fatty acid (SCFA) made from valeric acid.[6]

Valproate was first made in 1881 and came into medical use in 1962.[8] It is on the World Health Organization's List of Essential Medicines.[9] It is available as a generic medication.[1] The wholesale cost in the developing world is about US$0.40 per day as of 2015.[10] In the United States, the wholesale cost is roughly US$1.30 per day as of 2019.[11] It is marketed under the brand names Depakote, among others.[1] In 2017, it was the 126th most commonly prescribed medication in the United States, with more than five million prescriptions.[12][13]


Valproic acid (VPA) is an organic weak acid. The conjugate base is valproate. The sodium salt of the acid is sodium valproate and a coordination complex of the two is known as valproate semisodium.[14]

Medical uses

It is used primarily to treat epilepsy and bipolar disorder. It is also used to prevent migraine headaches.[15]


Valproate has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizures, absence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms.[15][16] It has also been successfully given intravenously to treat status epilepticus.[17][18]

Mental illness

Bipolar disorder

Valproate products are also used to treat manic or mixed episodes of bipolar disorder.[19][20]


A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia:[21]

There is limited evidence that adding valproate to antipsychotics may be effective for overall response and also for specific symptoms, especially in terms of excitement and aggression. Valproate was associated with a number of adverse events among which sedation and dizziness appeared more frequently than in the control groups.[21]

Dopamine dysregulation syndrome

Based upon five case reports, valproic acid may have efficacy in controlling the symptoms of the dopamine dysregulation syndrome that arise from the treatment of Parkinson's disease with levodopa.[22][23][24]


Valproate is also used to prevent migraine headaches. Because this medication can be potentially harmful to the fetus, valproate should be considered for those able to become pregnant only after the risks have been discussed.[25]


The medication has been tested in the treatment of AIDS and cancer, owing to its histone-deacetylase-inhibiting effects.[26]


The defined daily dose is 1.5 g (by mouth) or 1.5 g (parenteral) or 1.5 g (rectal)[2]

For adults for seizures it is generally started at 300 mg twice per day.[27] This does is than increased by 200 mg every three days to 500 to 1000 mg twice per day.[27] The lower end of the dosing scale is generally used for bipolar.[27]

For seizures, in children less than 20 kg, the dose is 10 mg/kg twice per day while the dose for children over 20 kg is 200 mg twice per day initially than increased to 10 to 15 mg per kg twice per day.[27]

Side effects

Valproate exacerbates methylmalonic aciduria. Note the periventricular white matter hyper intensities.

Most common side effects include:[25]

Serious adverse effects include:[25]

Valproic acid has a black box warning for hepatotoxicity, pancreatitis, and fetal abnormalities.[25]

There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height.[28][29][30][31] Valproic acid can also cause mydriasis, a dilation of the pupils.[32] There is evidence that shows valproic acid may increase the chance of polycystic ovary syndrome (PCOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PCOS is higher in women with epilepsy compared to those with bipolar disorder.[33] Weight gain is also possible.[34]


Valproate causes birth defects;[35] exposure during pregnancy is associated with about three times as many major abnormalities as usual, mainly spina bifida with the risks being related to the strength of medication used and use of more than one drug.[36][37] More rarely, with several other defects, including a "valproate syndrome".[38] Characteristics of this valproate syndrome include facial features that tend to evolve with age, including a triangle-shaped forehead, tall forehead with bifrontal narrowing, epicanthic folds, medial deficiency of eyebrows, flat nasal bridge, broad nasal root, anteverted nares, shallow philtrum, long upper lip and thin vermillion borders, thick lower lip and small downturned mouth.[39] While developmental delay is usually associated with altered physical characteristics (dysmorphic features), this is not always the case.[40]

Children of mothers taking valproate during pregnancy are at risk for lower IQs.[41][42][43] Maternal valproate use during pregnancy has been associated with a significantly higher probability of autism in the offspring.[44] A 2005 study found rates of autism among children exposed to sodium valproate before birth in the cohort studied were 8.9%.[45] The normal incidence for autism in the general population is estimated at less than one percent.[46] A 2009 study found that the 3-year-old children of pregnant women taking valproate had an IQ nine points lower than that of a well-matched control group. However, further research in older children and adults is needed.[47][48][49]

Sodium valproate has been associated with the rare condition paroxysmal tonic upgaze of childhood, also known as Ouvrier–Billson syndrome, from childhood or fetal exposure. This condition resolved after discontinuing valproate therapy.[50][51]

Women who intend to become pregnant should switch to a different medication if possible, or decrease their dose of valproate.[52] Women who become pregnant while taking valproate should be warned that it causes birth defects and cognitive impairment in the newborn, especially at high doses (although valproate is sometimes the only drug that can control seizures, and seizures in pregnancy could have even worse consequences). Studies have shown that taking folic acid can reduce the risk of congenital neural tube defects.[25] The use of valproate for migraine or bipolar disorder during pregnancy is contraindicated in the EU, and the medicines are not recommended for epilepsy during pregnancy unless there is no other effective treatment available.[53]


Valproate in elderly people with dementia caused increased sleepiness. More people stopped the medication for this reason. Additional side effects of weight loss and decreased food intake was also associated in one half of people who become sleepy.[25]


Contraindications include:


Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves.[54] It may also potentiate the CNS depressant effects of alcohol.[54] It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbitone) and itself.[54] It may also interact with:[25][54][56]

  • Aspirin: may increase valproate concentrations. May also interfere with valproate's metabolism.
  • Benzodiazepines: may cause CNS depression and there are possible pharmacokinetic interactions.
  • Carbapenem antibiotics: reduces valproate levels, potentially leading to seizures.
  • Cimetidine: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
  • Erythromycin: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
  • Ethosuximide: may increase ethosuximide concentrations and lead to toxicity.
  • Felbamate: may increase plasma concentrations of valproate.
  • Mefloquine: may increase valproate metabolism combined with the direct epileptogenic effects of mefloquine.
  • Oral contraceptives: may reduce plasma concentrations of valproate.
  • Primidone: may accelerate metabolism of valproate, leading to a decline of serum levels and potential breakthrough seizure.
  • Rifampin: increases the clearance of valproate, leading to decreased valproate concentrations
  • Warfarin: may increase warfarin concentration and prolong bleeding time.
  • Zidovudine: may increase zidovudine serum concentration and lead to toxicity.

Overdose and toxicity

Therapeutic range of valproic acid
Form Lower limit Upper limit Unit
Total (including
protein bound)
50[57] 125[57] µg/mL or mg/l
350[58] 700[58] μmol/L
Free 6[57] 22[57] µg/mL or mg/l
35[58] 70[58] μmol/L

Excessive amounts of valproic acid can result in sleepiness, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/l during controlled therapy, but may reach 150–1500 mg/l following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography.[59] In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9).[60]

In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body.[61][62] Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored.[25] Supplemental L-carnitine is indicated in patients having an acute overdose[63][64] and also prophylactically[63] in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly[65] than L-carnitine.



Although the mechanism of action of valproate is not fully understood,[54] traditionally, its anticonvulsant effect has been attributed to the blockade of voltage-gated sodium channels and increased brain levels of gamma-aminobutyric acid (GABA).[54] The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate.[54] In animals, sodium valproate raises cerebral and cerebellar levels of the inhibitory synaptic neurotransmitter, GABA, possibly by inhibiting GABA degradative enzymes, such as GABA transaminase, succinate-semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal cells.[54]

Prevention of neurotransmitter-induced hyperexcitability of nerve cells, via Kv7.2 channel and AKAP5, may also contribute to its mechanism.[66] Also, it has been shown to protect against a seizure-induced reduction in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) as a potential therapeutic mechanism.[67]

It also has histone-deacetylase-inhibiting effects. The inhibition of histone deacetylase, by promoting more transcriptionally active chromatin structures, likely presents the epigenetic mechanism for regulation of many of the neuroprotective effects attributed to valproic acid. Intermediate molecules mediating these effects include VEGF, BDNF, and GDNF.[68][69]

Endocrine actions

Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels.[70] In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations.[71] These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment.[70][71]

Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men.[72][73] High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid.[73]


The vast majority of valproate metabolism occurs in the liver.[74] In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as a glucuronide conjugate.[74] The other major pathway in the metabolism of valproate is mitochondrial beta-oxidation, which typically accounts for over 40% of an administered dose.[74] Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms.[74] Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine.[74]

Valproate is known to be metabolized by the Cytochrome P450 enzymes: CYP2A6, CYP2B6, CYP2C9, and CYP3A5.[74] It is also known to be metabolized by the UDP-glucuronosyltransferase enzymes: UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15.[74] Some of the known metabolites of valproate by these enzymes and uncharacterized enzymes include: 2-ene-valproic acid, 3Z-ene-valproic acid, 3E-ene-valproic acid, 4-ene-valproic acid, valproic acid β-O-glucuronide, 3-oxovalproic acid, 3-hydroxyvalproic acid, 4-hydroxyvalproic acid, 5-hydroxyvalproic acid, and valproyl-CoA, among others.[74]


Valproic acid is a branched short-chain fatty acid and a derivative of valeric acid.[6]


Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian.[75] Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats.[76] It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide.[77] Valproic acid has also been used for migraine prophylaxis and bipolar disorder.[78]

Society and culture


It is available as a generic medication.[1] The wholesale cost in the developing world is about US$0.40 per defined daily dose as of 2015.[10] In the United States, the National Average Drug Acquisition Cost is roughly US$1.30 per day for the short acting formulation as of 2019.[11] The price to a consumer in the United States for this amount is about $US2.30 per day as of 2019.[79] The long acting formulations are more expensive.[11] In the European Union, end-user costs are less than 0.60 EUR for an average daily dose in Germany.[80][citation needed]

Approval status

Indications United States
FDA-labelled indication?[3]
TGA-labelled indication?[15]
United Kingdom
MHRA-labelled indication?[81]
Literature support
Epilepsy Yes Yes Yes Limited (depends on the seizure type; it can help with certain kinds of seizures: drug-resistant epilepsy, partial and absence seizures, can be used against glioblastoma and other tumors both to improve survival and treat seizures, and against tonic–clonic seizures and status epilepticus).[82][83][84][85]
Bipolar mania Yes Yes Yes Limited.[86]
Bipolar depression No No No Moderate.[87]
Bipolar maintenance No No No Limited.[88]
Migraine prophylaxis Yes Yes (accepted) No Limited.
Acute migraine management No No No Only negative results.[89]
Schizophrenia No No No Weak evidence.[90]
Agitation in dementia No No No Weak evidence. Not recommended for agitation in people with dementia.[91] Increased rate of adverse effects, including a risk of serious adverse effects.[91]
Fragile X syndrome Yes (orphan) No No Limited.[69]
Familial adenomatous polyposis Yes (orphan) No No Limited.
Chronic pain & fibromyalgia No No No Limited.[92]
Alcohol hallucinosis No No No One randomised double-blind placebo-controlled trial.[93]
Intractable hiccups No No No Limited, five case reports support its efficacy, however.[94]
Non-epileptic myoclonus No No No Limited, three case reports support its efficacy, however.[95]
Cluster headaches No No No Limited, two case reports support its efficacy.[96]
West syndrome No No No A prospective clinical trial supported its efficacy in treating infantile spasms.[97]
HIV infection eradication No No No Double-blind placebo-controlled trials have been negative.[98][99][100]
Myelodysplastic syndrome No No No Several clinical trials have confirmed its efficacy as a monotherapy,[101] as an adjunct to tretinoin[101] and as an adjunct to hydralazine.[102]
Acute myeloid leukaemia No No No Two clinical trials have confirmed its efficacy in this indication as both a monotherapy and as an adjunct to tretinoin.[103][104][105]
Cervical cancer No No No One clinical trial supports its use here.[106]
Malignant melanoma No No No One phase II study has seemed to discount its efficacy.[107]
Breast cancer No No No A phase II study has supported its efficacy.[108]
Impulse control disorder No No No Limited.[109][110]

Off-label uses

In 2012, pharmaceutical company Abbott paid $1.6 billion in fines to federal and state governments for illegal promotion of off-label uses for Depakote, including the sedation of elderly nursing home residents.[111][112]


Sodium valproate
Other namesvalproate sodium (USAN US)
  • sodium 2-propylpentanoate
License data
CAS Number
  • 1069-66-5 checkY
PubChem CID
Chemical and physical data
Molar mass166.196 g·mol−1
3D model (JSmol)
  • CCCC(CCC)C(=O)[O-].[Na+]
  • InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1 checkY
Valproate semisodium
Trade namesDepakote, others
Other namessemisodium valproate, divalproex sodium (USAN US)
  • sodium;2-propylpentanoate;2-propylpentanoic acid
License data
Chemical and physical data
Molar mass310.410 g·mol−1
3D model (JSmol)
  • CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]
  • InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1 checkY

Valproate exists in two main molecular variants: sodium valproate and valproic acid without sodium (often implied by simply valproate). A mixture between these two is termed semisodium valproate. It is unclear whether there is any difference in efficacy between these variants, except from the fact that about 10% more of sodium valproate is needed than valproic acid without sodium to compensate for the sodium itself.[113]

Brand names of valproic acid

Branded products include:

Brand names of sodium valproate

  • Tablets – Diplexil-R by Bial.
United States
  • Intravenous injection – Depacon by Abbott Laboratories.
  • Syrup – Depakene by Abbott Laboratories. (Note Depakene capsules are valproic acid).
  • Depakote tablets are a mixture of sodium valproate and valproic acid.
  • Tablets – Eliaxim by Bial.
  • Epilim Crushable Tablets Sanofi[115]
  • Epilim Sugar Free Liquid Sanofi[115]
  • Epilim Syrup Sanofi[115]
  • Epilim Tablets Sanofi[115]
  • Sodium Valproate Sandoz Tablets Sanofi
  • Valpro Tablets Alphapharm
  • Valproate Winthrop Tablets Sanofi
  • Valprease tablets Sigma
New Zealand
  • Epilim by Sanofi-Aventis

All the above formulations are Pharmac-subsidised.[116]

  • Depakote Tablets (as in USA)
  • Tablets – Orlept by Wockhardt and Epilim by Sanofi
  • Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
  • Syrup – Epilim by Sanofi-Aventis
  • Intravenous injection – Epilim Intravenous by Sanofi
  • Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
  • Enteric-coated tablets – Epilim EC200 by Sanofi is a 200-mg sodium valproate enteric-coated tablet.
UK only
  • Capsules – Episenta prolonged release by Beacon
  • Sachets – Episenta prolonged release by Beacon
  • Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden
  • Tablets – Orfiril by Desitin Pharmaceuticals
  • Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa
  • Syrup – Convulex by Byk Madaus[117]
  • Tablets – Epilim by Sanofi-synthelabo
  • Tablets – Epilim by Sanofi-Aventis
  • Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
  • Tablets – Depakene by Kyowa Hakko Kirin
  • Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
  • Syrup – Depakene by Kyowa Hakko Kogyo

In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.

  • Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
  • Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)

Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.

India, Russia and CIS countries
  • Valparin Chrono by Torrent Pharmaceuticals India
  • Valprol CR by Intas Pharmaceutical (India)
  • Encorate Chrono by Sun Pharmaceutical (India)
  • Serven Chrono by Leeven APL Biotech (India)

Brand names of valproate semisodium

  • Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil
  • Canada – Epival by Abbott Laboratories
  • Mexico – Epival and Epival ER (extended release) by Abbott Laboratories
  • United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics
  • United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics[25]
  • India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
  • Germany – Ergenyl Chrono by Sanofi-Aventis and generics
  • Chile – Valcote and Valcote ER by Abbott Laboratories
  • France and other European countries — Depakote
  • Peru – Divalprax by AC Farma Laboratories
  • China – Diprate OD


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 "Valproic Acid". The American Society of Health-System Pharmacists. Archived from the original on 2017-07-31. Retrieved Oct 23, 2015.
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". Archived from the original on 1 July 2021. Retrieved 22 September 2020.
  3. 3.0 3.1 3.2 3.3 "Depakene, Stavzor (valproic acid) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 21 February 2014. Retrieved 13 February 2014.
  4. "Valproate banned without the pregnancy prevention programme". GOV.UK. Archived from the original on 24 April 2018. Retrieved 26 April 2018.
  5. Owens MJ, Nemeroff CB (2003). "Pharmacology of valproate". Psychopharmacol Bull. 37 Suppl 2: 17–24. PMID 14624230.
  6. 6.0 6.1 6.2 Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE (April 2013). "Valproic acid pathway: pharmacokinetics and pharmacodynamics". Pharmacogenet. Genomics. 23 (4): 236–241. doi:10.1097/FPC.0b013e32835ea0b2. PMC 3696515. PMID 23407051.
  7. "Valproic acid". DrugBank. University of Alberta. 29 July 2017. Archived from the original on 31 July 2017. Retrieved 30 July 2017.
  8. Scott, D.F. (1993). The history of epileptic therapy : an account of how medication was developed (1. publ. ed.). Carnforth u.a.: Parthenon Publ. Group. p. 131. ISBN 9781850703914. Archived from the original on 2019-07-01. Retrieved 2017-09-17.
  9. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  10. 10.0 10.1 International Medical Products Price Guide (PDF) (2015 ed.). Management Sciences for Health. 2016. p. A-140. Archived from the original on 27 August 2021. Retrieved 23 February 2020. Cite error: Invalid <ref> tag; name "ERC2015" defined multiple times with different content
  11. 11.0 11.1 11.2 "NADAC as of 2019-11-27 |". Centers for Medicare and Medicaid Services. Archived from the original on 2020-07-11. Retrieved 25 November 2019. Cite error: Invalid <ref> tag; name "NADAC2019" defined multiple times with different content
  12. "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
  13. "Divalproex Sodium - Drug Usage Statistics". ClinCalc. Archived from the original on 27 August 2021. Retrieved 11 April 2020.
  14. Brayfield, Alison (ed.). Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Archived from the original on August 27, 2021. Retrieved March 3, 2018.
  15. 15.0 15.1 15.2 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  16. Löscher W (2002). "Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy". CNS Drugs. 16 (10): 669–694. doi:10.2165/00023210-200216100-00003. PMID 12269861. S2CID 67999301.
  17. Olsen KB, Taubøll E, Gjerstad L (2007). "Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults". Acta Neurol. Scand. Suppl. 187: 51–4. doi:10.1111/j.1600-0404.2007.00847.x. PMID 17419829.
  18. Kwan SY (2010). "The role of intravenous valproate in convulsive status epilepticus in the future" (PDF). Acta Neurol Taiwan. 19 (2): 78–81. PMID 20830628.[permanent dead link]
  19. "Valproate Information". Archived from the original on 2015-05-03. Retrieved 2015-04-24.
  20. Jochim, Janina; Rifkin-Zybutz, Raphael; Geddes, John; Cipriani, Andrea (7 October 2019). "Valproate for acute mania". Cochrane Database of Systematic Reviews. 10: CD004052. doi:10.1002/14651858.CD004052.pub2. PMC 6797024. PMID 31621892.
  21. 21.0 21.1 Wang, Y; Xia, J; Helfer, B (2016). "Valproate for schizophrenia". Cochrane Database of Systematic Reviews. 11: CD004028.pub4. doi:10.1002/14651858.CD004028.pub4. PMC 6734130. PMID 27884042. Archived from the original on 2017-07-29.
  22. Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G (2014). "Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review". Biomed Res Int. 2014: 1–9. doi:10.1155/2014/728038. PMC 4119624. PMID 25114917.
  23. Connolly B, Fox SH (2014). "Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease". Neurotherapeutics. 11 (1): 78–91. doi:10.1007/s13311-013-0238-x. PMC 3899484. PMID 24288035.
  24. Averbeck BB, O'Sullivan SS, Djamshidian A (2014). "Impulsive and compulsive behaviors in Parkinson's disease". Annu Rev Clin Psychol. 10: 553–80. doi:10.1146/annurev-clinpsy-032813-153705. PMC 4197852. PMID 24313567.
  25. 25.0 25.1 25.2 25.3 25.4 25.5 25.6 25.7 25.8 "Depakote- divalproex sodium tablet, delayed release". Archived from the original on 5 March 2016. Retrieved 10 November 2015.
  26. Činčárová L, Zdráhal Z, Fajkus J (2013). "New perspectives of valproic acid in clinical practice". Expert Opin Investig Drugs. 22 (12): 1535–1547. doi:10.1517/13543784.2013.853037. PMID 24160174. S2CID 11855893.
  27. 27.0 27.1 27.2 27.3 "VALPROIC acid = SODIUM VALPROATE oral - Essential drugs". Archived from the original on 27 August 2021. Retrieved 17 August 2020.
  28. Wu S, Legido A, De Luca F (2004). "Effects of valproic acid on longitudinal bone growth". J Child Neurol. 19 (1): 26–30. doi:10.1177/088307380401900105011. PMID 15032379. S2CID 19827846.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  29. Robinson PB, Harvey W, Belal MS (1988). "Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate". Br J Exp Pathol. 69 (1): 17–22. PMC 2013195. PMID 3126792.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  30. Guo CY, Ronen GM, Atkinson SA (2002). "Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy". Epilepsia. 42 (9): 1141–7. doi:10.1046/j.1528-1157.2001.416800.x. PMID 11580761.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  31. Guo CY, Ronen GM, Atkinson SA (2002). "Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy". Epilepsia. 42 (9): 1141–7. doi:10.1046/j.1528-1157.2001.416800.x. PMID 11580761.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. "Could Depakote cause Mydriasis". 2014-11-18. Archived from the original on 2014-12-05. Retrieved 2015-04-24.
  33. Bilo, Leonilda; Meo, Roberta (October 2008). "Polycystic ovary syndrome in women using valproate: a review". Gynecological Endocrinology. 24 (10): 562–70. doi:10.1080/09513590802288259. PMID 19012099. S2CID 36426338.
  34. Chukwu, J; Delanty, N; Webb, D; Cavalleri, GL (January 2014). "Weight change, genetics and antiepileptic drugs". Expert Review of Clinical Pharmacology. 7 (1): 43–51. doi:10.1586/17512433.2014.857599. PMID 24308788. S2CID 33444886.
  35. New evidence in France of harm from epilepsy drug valproate Archived 2017-04-21 at the Wayback Machine BBC, 2017
  36. Koch S, Göpfert-Geyer I, Jäger-Roman E, et al. (February 1983). "[Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development]". Dtsch. Med. Wochenschr. (in German). 108 (7): 250–7. doi:10.1055/s-2008-1069536. PMID 6402356.{{cite journal}}: CS1 maint: unrecognized language (link)
  37. Moore SJ, Turnpenny P, Quinn A, et al. (July 2000). "A clinical study of 57 children with fetal anticonvulsant syndromes". J. Med. Genet. 37 (7): 489–97. doi:10.1136/jmg.37.7.489. PMC 1734633. PMID 10882750.
  38. Ornoy A (2009). "Valproic acid in pregnancy: how much are we endangering the embryo and fetus?". Reprod. Toxicol. 28 (1): 1–10. doi:10.1016/j.reprotox.2009.02.014. PMID 19490988.
  39. Kulkarni ML, Zaheeruddin M, Shenoy N, Vani HN (2006). "Fetal valproate syndrome". Indian J Pediatr. 73 (10): 937–939. doi:10.1007/bf02859291. PMID 17090909.
  40. Adab N, Kini U, Vinten J, et al. (November 2004). "The longer term outcome of children born to mothers with epilepsy". J. Neurol. Neurosurg. Psychiatry. 75 (11): 1575–83. doi:10.1136/jnnp.2003.029132. PMC 1738809. PMID 15491979. Archived from the original on 2008-09-06. This argues that the fetal valproate syndrome constitutes a real clinical entity that includes developmental delay and cognitive impairments, but that some children might exhibit some developmental delay without marked dysmorphism.
  41. Umur AS, Selcuki M, Bursali A, Umur N, Kara B, Vatansever HS, Duransoy YK (2012). "Simultaneous folate intake may prevent adverse effect of valproic acid on neurulating nervous system". Childs Nerv Syst. 28 (5): 729–737. doi:10.1007/s00381-011-1673-9. PMID 22246336. S2CID 20344828.
  42. Cassels, Caroline (December 8, 2006). "NEAD: In Utero Exposure To Valproate Linked to Poor Cognitive Outcomes in Kids". Medscape. Archived from the original on July 31, 2011. Retrieved 2007-05-23.
  43. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC (2006). "In utero antiepileptic drug exposure: fetal death and malformations". Neurology. 67 (3): 407–412. doi:10.1212/01.wnl.0000227919.81208.b2. PMC 1986655. PMID 16894099.
  44. Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M (2013). "Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism". JAMA. 309 (16): 1696–1703. doi:10.1001/jama.2013.2270. PMC 4511955. PMID 23613074.
  45. Rasalam AD, Hailey H, Williams JH, et al. (August 2005). "Characteristics of fetal anticonvulsant syndrome associated autistic disorder". Dev Med Child Neurol. 47 (8): 551–5. doi:10.1017/S0012162205001076. PMID 16108456.
  46. Autism Society of America: About Autism Archived 2011-01-10 at the Wayback Machine
  47. I.Q. Harmed by Epilepsy Drug in Utero Archived 2015-12-29 at the Wayback Machine By RONI CARYN RABIN, New York Times, April 15, 2009
  48. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW (2009). "Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs". N. Engl. J. Med. 360 (16): 1597–1605. doi:10.1056/NEJMoa0803531. PMC 2737185. PMID 19369666.
  49. Valproate Products: Drug Safety Communication - Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy) Archived 2011-09-02 at the Wayback Machine. FDA. June 2011
  50. Luat, AF (20 September 2007). "Paroxysmal tonic upgaze of childhood with co-existent absence epilepsy". Epileptic Disorders. 9 (3): 332–6. doi:10.1684/epd.2007.0119 (inactive 2020-06-30). PMID 17884759.{{cite journal}}: CS1 maint: DOI inactive as of June 2020 (link)
  51. Ouvrier, RA (July 1988). "Benign paroxysmal tonic upgaze of childhood". Journal of Child Neurology. 3 (3): 177–80. doi:10.1177/088307388800300305. PMID 3209843. S2CID 38127378.
  52. Valproate Not To Be Used for Migraine During Pregnancy, FDA Warns Archived 2013-07-09 at the Wayback Machine
  53. "New measures to avoid valproate exposure in pregnancy endorsed". European Medicines Agency. 31 May 2018. Archived from the original on 16 October 2019.
  54. 54.00 54.01 54.02 54.03 54.04 54.05 54.06 54.07 54.08 54.09 54.10 54.11 54.12 54.13 54.14 "Valpro sodium valproate" (PDF). TGA eBusiness Services. Alphapharm Pty Limited. 16 December 2013. Archived from the original on 27 August 2021. Retrieved 14 February 2014.
  55. "Depakote 250mg Tablets - Summary of Product Characteristics". electronic Medicines Compendium. Sanofi. 28 November 2013. Archived from the original on 1 February 2014. Retrieved 18 January 2014.
  56. Herzog, Andrew; Farina, Erin (June 9, 2005). "Serum Valproate Levels with Oral Contraceptive Use". Epilepsia. 46 (6): 970–971. doi:10.1111/j.1528-1167.2005.00605.x. PMID 15946343.
  57. 57.0 57.1 57.2 57.3 Bentley, Suzanne (Dec 11, 2013). "Valproic Acid Level". Medscape. Archived from the original on 2015-05-04. Retrieved 2015-06-05.
  58. 58.0 58.1 58.2 58.3 "Free Valproic Acid Assay (Reference — 2013.03.006) Notice of Assessment" (PDF). Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS's permission. April 2014. Archived (PDF) from the original on 2016-03-03. Retrieved 2015-06-05.
  59. Sztajnkrycer MD (2002). "Valproic acid toxicity: overview and management". J. Toxicol. Clin. Toxicol. 40 (6): 789–801. doi:10.1081/CLT-120014645. PMID 12475192. S2CID 23031095.
  60. Patsalos PN, Berry DJ (2013). "Therapeutic drug monitoring of antiepileptic drugs by use of saliva". Ther Drug Monit. 35 (1): 4–29. doi:10.1097/FTD.0b013e31827c11e7. PMID 23288091. S2CID 15338188.
  61. Thanacoody RH (2009). "Extracorporeal elimination in acute valproic acid poisoning". Clin Toxicol. 47 (7): 609–616. doi:10.1080/15563650903167772. PMID 19656009. S2CID 13592043.
  62. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1622-1626.
  63. 63.0 63.1 Lheureux PE, Penaloza A, Zahir S, Gris M (2005). "Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?". Crit Care. 9 (5): 431–440. doi:10.1186/cc3742. PMC 1297603. PMID 16277730.
  64. Mock CM, Schwetschenau KH (2012). "Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy". Am J Health Syst Pharm. 69 (1): 35–39. doi:10.2146/ajhp110049. PMID 22180549.
  65. Matsuoka M, Igisu H (1993). "Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia". Biochem. Pharmacol. 46 (1): 159–164. doi:10.1016/0006-2952(93)90360-9. PMID 8347126.
  66. Kay, Hee Yeon; Greene, Derek L.; Kang, Seungwoo; Kosenko, Anastasia; Hoshi, Naoto (2015-10-01). "M-current preservation contributes to anticonvulsant effects of valproic acid". The Journal of Clinical Investigation. 125 (10): 3904–3914. doi:10.1172/JCI79727. ISSN 0021-9738. PMC 4607138. PMID 26348896.
  67. Chang P, Walker MC, Williams RS (2014). "Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid". Neurobiol. Dis. 62: 296–306. doi:10.1016/j.nbd.2013.10.017. PMC 3898270. PMID 24148856.
  68. Kostrouchová M, Kostrouch Z, Kostrouchová M (2007). "Valproic acid, a molecular lead to multiple regulatory pathways" (PDF). Folia Biol. (Praha). 53 (2): 37–49. PMID 17448293. Archived (PDF) from the original on 2014-02-21.
  69. 69.0 69.1 Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013). "Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder". Pharmacol. Rev. 65 (1): 105–142. doi:10.1124/pr.111.005512. PMC 3565922. PMID 23300133.
  70. 70.0 70.1 Death AK, McGrath KC, Handelsman DJ (2005). "Valproate is an anti-androgen and anti-progestin" (PDF). Steroids. 70 (14): 946–53. doi:10.1016/j.steroids.2005.07.003. hdl:10453/16875. PMID 16165177. S2CID 25958985. Archived (PDF) from the original on 2021-08-27. Retrieved 2018-07-27.
  71. 71.0 71.1 Wyllie E, Cascino GD, Gidal BE, Goodkin HP (17 February 2012). Wyllie's Treatment of Epilepsy: Principles and Practice. Lippincott Williams & Wilkins. pp. 288–. ISBN 978-1-4511-5348-4. Archived from the original on 6 June 2014.
  72. Uchida, Hiroshi; Maruyama, Tetsuo; Arase, Toru; Ono, Masanori; Nagashima, Takashi; Masuda, Hirotaka; Asada, Hironori; Yoshimura, Yasunori (2005). "Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription". Reproductive Medicine and Biology. 4 (2): 115–122. doi:10.1111/j.1447-0578.2005.00101.x. ISSN 1445-5781. PMC 5891791. PMID 29662388.
  73. 73.0 73.1 Isojärvi, Jouko I T; Taubøll, Erik; Herzog, Andrew G (2005). "Effect of Antiepileptic Drugs on Reproductive Endocrine Function in Individuals with Epilepsy". CNS Drugs. 19 (3): 207–223. doi:10.2165/00023210-200519030-00003. ISSN 1172-7047. PMID 15740176. S2CID 9893959.
  74. 74.0 74.1 74.2 74.3 74.4 74.5 74.6 74.7 "Pharmacology". Valproic Acid. DrugBank. University of Alberta. 31 August 2017. Archived from the original on 31 July 2017. Retrieved 30 July 2017.
  75. Burton BS (1882). "On the propyl derivatives and decomposition products of ethylacetoacetate". Am. Chem. J. 3: 385–395.
  76. Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M (1963). "[Pharmacodynamic properties of N-dipropylacetic acid]" [Pharmacodynamic properties of N-dipropylacetic acid]. Thérapie (in French). 18: 435–438. PMID 13935231.{{cite journal}}: CS1 maint: unrecognized language (link)
  77. Perucca E (2002). "Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience". CNS Drugs. 16 (10): 695–714. doi:10.2165/00023210-200216100-00004. PMID 12269862. S2CID 803106.
  78. Henry TR (2003). "The history of valproate in clinical neuroscience". Psychopharmacol Bull. 37 Suppl 2: 5–16. PMID 14624229.
  79. "Valproic acid Prices, Coupons & Patient Assistance Programs". Archived from the original on 6 March 2021. Retrieved 25 November 2019.
  80. Regular pharmacy price, including all taxes, et cetera: less than 34,43 EUR for 200 controlled release pills with 500mg each; date: 2016-11-30
  81. Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
  82. Rimmer EM, Richens A (May–June 1985). "An update on sodium valproate". Pharmacotherapy. 5 (3): 171–84. doi:10.1002/j.1875-9114.1985.tb03413.x. PMID 3927267.
  83. Glauser, Tracy A; Cnaan, Avital; Shinnar, Shlomo; Hirtz, Deborah G; Dlugos, Dennis; Masur, David; Clark, Peggy O; Capparelli, Edmund V; Adamson, Peter C (2010). "Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy". New England Journal of Medicine. 362 (9): 790–9. doi:10.1056/NEJMoa0902014. PMC 2924476. PMID 20200383.
  84. Jiang, Mei (6 April 2015). "Co-Administration of Valproic Acid and Lamotrigine in the Treatment of Refractory Epilepsy (P1.238)". Neurology. 84 (14 Supplement): P1.238. Archived from the original on 27 August 2021. Retrieved 4 May 2015 – via
  85. Berendsen, S.; Kroonen, J.; Seute, T.; Snijders, T.; Broekman, M. L. D.; Spliet, W. G. M.; Willems, M.; Artesi, M.; Bours, V.; Robe, P. A. (1 September 2014). "O9.06 * Prognostic Relevance and Oncogenic Correlates of Epilepsy in Glioblastoma Patients". Neuro-Oncology. 16 (suppl_2): ii21. doi:10.1093/neuonc/nou174.77. PMC 4185847.
  86. Vasudev K, Mead A, Macritchie K, Young AH (2012). "Valproate in acute mania: is our practice evidence based?". Int J Health Care Qual Assur. 25 (1): 41–52. doi:10.1108/09526861211192395. PMID 22455007.
  87. Bond DJ, Lam RW, Yatham LN (2010). "Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis". J Affect Disord. 124 (3): 228–334. doi:10.1016/j.jad.2009.11.008. PMID 20044142.
  88. Haddad PM, Das A, Ashfaq M, Wieck A (2009). "A review of valproate in psychiatric practice". Expert Opin Drug Metab Toxicol. 5 (5): 539–51. doi:10.1517/17425250902911455. PMID 19409030. S2CID 74028228.
  89. Frazee LA, Foraker KC (2008). "Use of intravenous valproic acid for acute migraine". Ann Pharmacother. 42 (3): 403–7. doi:10.1345/aph.1K531. PMID 18303140. S2CID 207263036.
  90. Wang, Yijun; Xia, Jun; Helfer, Bartosz; Li, Chunbo; Leucht, Stefan (2016). "Valproate for schizophrenia". The Cochrane Database of Systematic Reviews. 11: CD004028. doi:10.1002/14651858.CD004028.pub4. ISSN 1469-493X. PMC 6734130. PMID 27884042.
  91. 91.0 91.1 Baillon, Sarah F.; Narayana, Usha; Luxenberg, Jay S.; Clifton, Andrew V. (2018-10-05). "Valproate preparations for agitation in dementia". The Cochrane Database of Systematic Reviews. 10: CD003945. doi:10.1002/14651858.CD003945.pub4. ISSN 1469-493X. PMC 6516950. PMID 30293233.
  92. Gill D, Derry S, Wiffen PJ, Moore RA (2011). "Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults". Cochrane Database Syst Rev (10): CD009183. doi:10.1002/14651858.CD009183.pub2. PMC 6540387. PMID 21975791.
  93. Aliyev ZN, Aliyev NA (July–August 2008). "Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study" (PDF). Alcohol Alcohol. 43 (4): 456–459. doi:10.1093/alcalc/agn043. PMID 18495806.
  94. Jacobson PL, Messenheimer JA, Farmer TW (1981). "Treatment of intractable hiccups with valproic acid". Neurology. 31 (11): 1458–60. doi:10.1212/WNL.31.11.1458. PMID 6796902. S2CID 1578958.
  95. Sotaniemi K (1982). "Valproic acid in the treatment of nonepileptic myoclonus". Arch. Neurol. 39 (7): 448–9. doi:10.1001/archneur.1982.00510190066025. PMID 6808975.
  96. Wheeler SD (July–August 1998). "Significance of migrainous features in cluster headache: divalproex responsiveness". Headache. 38 (7): 547–51. doi:10.1046/j.1526-4610.1998.3807547.x. PMID 15613172.
  97. Siemes H, Spohr HL, Michael T, Nau H (September–October 1988). "Therapy of infantile spasms with valproate: results of a prospective study". Epilepsia. 29 (5): 553–60. doi:10.1111/j.1528-1157.1988.tb03760.x. PMID 2842127.
  98. Smith SM (2005). "Valproic acid and HIV-1 latency: beyond the sound bite" (PDF). Retrovirology. 2 (1): 56. doi:10.1186/1742-4690-2-56. PMC 1242254. PMID 16168066. Archived (PDF) from the original on 2015-09-24.
  99. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR (2012). "Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study". HIV Med. 13 (5): 291–6. doi:10.1111/j.1468-1293.2011.00975.x. PMID 22276680.
  100. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM (2010). "Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection". PLOS ONE. 5 (2): e9390. Bibcode:2010PLoSO...5.9390A. doi:10.1371/journal.pone.0009390. PMC 2826423. PMID 20186346.
  101. 101.0 101.1 Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A'Hern R (2001). "A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain" (PDF). J Pain Symptom Manage. 21 (3): 204–9. doi:10.1016/S0885-3924(00)00266-9. PMID 11239739.[permanent dead link]
  102. Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A (2011). "Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial". Ann. Hematol. 90 (4): 379–387. doi:10.1007/s00277-010-1090-2. PMID 20922525. S2CID 13437134.
  103. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG (2005). "Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia". Cancer. 104 (12): 2717–2725. doi:10.1002/cncr.21589. PMID 16294345.
  104. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N (2006). "The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia". Cancer. 106 (1): 112–119. doi:10.1002/cncr.21552. PMID 16323176.
  105. Fredly H, Gjertsen BT, Bruserud O (2013). "Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents" (PDF). Clin Epigenetics. 5 (1): 12. doi:10.1186/1868-7083-5-12. PMC 3733883. PMID 23898968. Archived (PDF) from the original on 2014-02-21.
  106. Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, González-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S, Dueñas-González A (2011). "A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results". Med. Oncol. 28 Suppl 1: S540–6. doi:10.1007/s12032-010-9700-3. PMID 20931299. S2CID 207372333.
  107. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, Nolè F, Munzone E, Salmaggi A, Goldhirsch A, Pelicci PG, Testori A (2009). "A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma". Br. J. Cancer. 100 (1): 28–36. doi:10.1038/sj.bjc.6604817. PMC 2634690. PMID 19127265.
  108. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D (2009). "Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC" (PDF). Clin. Cancer Res. 15 (7): 2488–96. doi:10.1158/1078-0432.CCR-08-1930. PMID 19318486. S2CID 3230087. Archived (PDF) from the original on 2021-08-27. Retrieved 2014-02-13.
  109. Hicks CW, Pandya MM, Itin I, Fernandez HH (2011). "Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease". Parkinsonism Relat. Disord. 17 (5): 379–81. doi:10.1016/j.parkreldis.2011.03.003. PMID 21459656.
  110. Sriram A, Ward HE, Hassan A, Iyer S, Foote KD, Rodriguez RL, McFarland NR, Okun MS (2013). "Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease". J. Neurol. 260 (2): 521–7. doi:10.1007/s00415-012-6669-1. PMID 23007193. S2CID 21544457.
  111. Aizenman, N. C. (7 May 2012). "Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote". Washington Post. Archived from the original on 28 June 2018. Retrieved 27 June 2018.
  112. Schmidt, Michael; Thomas, Katie (8 May 2012). "Abbott settles marketing lawsuit". New York Times. Archived from the original on 28 June 2018. Retrieved 27 June 2018.
  113. David Taylor; Carol Paton; Shitij Kapur (2009). The Maudsley Prescribing Guidelines, Tenth Edition (10, revised ed.). CRC Press. p. 124. ISBN 9780203092835. Archived from the original on 2020-07-11. Retrieved 2017-09-17.
  114. "Depakene- valproic acid capsule, liquid filled". DailyMed. 19 September 2019. Archived from the original on 11 July 2020. Retrieved 14 April 2020.
  115. 115.0 115.1 115.2 115.3 "Australian product information epilim (sodium valproate) crushable tablets, enteric-coated tablets, syrup, liquid" (PDF). TGA eBS. 15 April 2020. Archived from the original on 15 March 2020. Retrieved 15 April 2020.
  116. "Sodium valproate -- Pharmaceutical Schedule". Pharmaceutical Management Agency. Archived from the original on 4 March 2016. Retrieved 22 June 2014.
  117. "South African Electronic Package Inserts: Convulex". Archived from the original on 2010-08-12. Retrieved 2006-01-02.

External links

  • "Valproic acid". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2016-05-10. Retrieved 2020-04-15.
  • "Valproate sodium". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-07-11. Retrieved 2020-04-15.
  • "Divalproex sodium". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2016-05-10. Retrieved 2020-04-15.